Title : Interpretation of liver stiffness measurement based approach for the monitoring of hepatitis B patients with antiviral therapy : a 2-year prospective study Running head : Liver stiffness for liver fibrosis monitoring Authors :
Xieer Liang,Qing Xie,Deming Tan,Qin Ning,Junqi Niu,Xuefan Bai,Shijun Chen,Jun Cheng,Yanyan Yu,Hao Wang,Min Xu,Guangfeng Shi,Mobin Wan,Xinyue Chen,Hong Tang,Jifang Sheng,Xiaoguang Dou,Junping Shi,Hong Ren,Maorong Wang,Hongfei Zhang,Zhiliang Gao,Chengwei Chen,Hong Ma,Yongpeng Chen,Rong Fan,Jian Sun,Jidong Jia,Jinlin Hou
2017-01-01
Abstract:Liver biopsy is not routinely performed in treated chronic hepatitis B. Liver stiffness measurement has been validated for non-invasive liver fibrosis assessment in pre-treatment chronic hepatitis B but has not been assessed for fibrosis monitoring during antiviral therapy. A cc ep te d A rt ic le This article is protected by copyright. All rights reserved. Liver stiffness was systemically monitored by Fibroscan every 6 months in a cohort of patients with hepatitis B receiving antiviral therapy and compared with liver biopsies at baseline and week 104. A total of 534 hepatitis B e antigen positive treatment-naive patients receiving telbivudine based therapy with qualified liver stiffness measurement at baseline and week 104 were analyzed, 164 of which had adequate paired liver biopsies. Liver stiffness decreased rapidly (-2.2 kPa/24 weeks) in parallel with alanine aminotransferase (ALT) from 8.6 (2.6 49.5) kPa at baseline to 6.1 (2.2 37.4) kPa at week 24. Interestingly, liver stiffness decreased slowly (-0.3 kPa/24 weeks) but continually from week 24 to week 104 (6.1 vs. 5.3 kPa, P <0.001) while ALT levels remained stable within the normal range. More importantly, liver stiffness declined significantly irrespective of baseline ALT levels and liver necro-inflammation grades. From baseline to week 104, the proportion of patients with no or mild fibrosis (Ishak, 0 2) increased from 74.4% (122/164) to 93.9% (154/164). Multivariate analysis revealed that percentage decline of 52-week liver stiffness from baseline was independently associated with 104-week liver fibrosis regression (odds ratio, 3.742; P =0.016). Early decline of 52-week liver stiffness from baseline may reflect the remission of both liver inflammation and fibrosis and was predictive of 104-week fibrosis regression in treated patients with chronic hepatitis B. Keyworks: antiviral therapy; fibrosis regression; hepatitis B; liver stiffness